From: Reuters
Published January 25, 2008 02:58 PM

FDA says reviewing Merck, Schering-Plough drug

WASHINGTON (Reuters) - U.S. health officials said on Friday they would review whether to take regulatory action over Merck & Co Inc and Schering-Plough's cholesterol medicine Vytorin following the drug's failure to work better than a generic drug in a study of plaque build-up in neck arteries.

The Food and Drug Administration said it had not yet received a final report on the study, called Enhance. The agency's review will take about six months after the final report is received, the FDA said.

(Reporting by Lisa Richwine; Editing by Tim Dobbyn)

Terms of Use | Privacy Policy

2017©. Copyright Environmental News Network